Literature DB >> 9242945

Survival for up to six months in calves supported with an implantable axial flow ventricular assist device.

M Macha1, P Litwak, K Yamazaki, M Kameneva, J P Kerrigan, J F Antaki, K C Butler, D C Thomas, L P Taylor, R L Kormos, B P Griffith, H S Borovetz.   

Abstract

This paper summarizes the authors' in vivo experience to date with an implantable axial flow blood pump designed for long-term ventricular support. This small, valveless pump with blood-lubricated bearings has been implanted in six calves (83 +/- 6 kg) as a left ventricular assist device (LVAS). The left ventricle and descending thoracic aorta were cannulated by left thoracotomy, and the pump was placed in a subcutaneous pocket below the costal margin. Animals remained hemodynamically stable throughout the course of support during partial left ventricular bypass. Five animals were killed after 15, 27, 52, 57, and 181 days. The longest survivor (181 days) demonstrated normal pump function at the time death. Pump speed was maintained at 10,100 +/- 100 rpm, with an average pump flow rate of 4.9 +/- 0.5 L/min under resting physiologic conditions. Average plasma free hemoglobin was 17.4 +/- 7.5 mg/dl. Renal, hepatic, and hematologic indices remained within physiologic range in all of these animals, except during the immediate postoperative period. Histopathologic analyses of major organs after death revealed small renal cortical infarcts in five of six animals; the remaining organs were normal. These animal studies support the feasibility of this small implanted axial flow pump for long-term ventricular assistance.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9242945

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   2.872


  1 in total

1.  Pre-clinical Implants of the Levitronix PediVAS® Pediatric Ventricular Assist Device - Strategy for Regulatory Approval.

Authors:  Timothy M Maul; Ergin Kocyildirim; John D Marks; Shawn G Bengston; Salim E Olia; Patrick M Callahan; Marina V Kameneva; Stephen Franklin; Harvey S Borovetz; Kurt A Dasse; Peter D Wearden
Journal:  Cardiovasc Eng Technol       Date:  2011-10-27       Impact factor: 2.495

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.